Xue Zhang

Xue Zhang has over 18 years of experience in the biotechnology and pharmaceutical industry. In 2003, they began their career as a Research Scientist at Novasite Pharmaceuticals. Xue then moved to the Sanford Burnham Prebys Medical Discovery Institute in 2004 as a Scientist, where they identified and characterized novel genes/signaling pathways regulating the metabolism of Aβ-amyloid. In 2007, Xue became an Institute Fellow at the Genomics Institute of the Novartis Research Foundation, where they conducted research to find a treatment for age-related macular degeneration (AMD). In 2010, they joined AnaptysBio as a Scientist II and was responsible for antibody discovery, affinity maturation and functional characterization of therapeutic antibodies. In 2014, Xue began working at Gilead Sciences as a Research Scientist and was later promoted to Senior Research Scientist (AD). That same year, they also joined Ambrx as a Scientist. In 2021, Xue became Co-Founder & SVP Cell Therapy at Fresh Wind Biotechnologies, and in 2022 they were appointed Director of Protein Sciences at Adcentrx Therapeutics, where they manage the Protein Sciences group for antibody discovery, characterization and early development.

Xue Zhang obtained their BS in Biochemistry from Nankai University. Xue then pursued a PhD in Biochemistry from Baylor College of Medicine, which they completed in 2003. In 2017, Xue Zhang obtained a Certificate for Clinical Research Conduct and Management from UC Berkeley Extension. Xue also took courses at the University of Houston, though no degree was obtained. In 2020, Xue Zhang obtained a Clinical Operations certification from UC Berkeley Extension. In 2021, they obtained a Regulatory Affairs Certification (RAC) from UC Berkeley Extension.